Expansion Potential EVA Pharma operates in over 60 countries across the Middle East and Africa with a rapidly growing presence in oncology, immunotherapy and high-tech biopharmaceuticals, signaling strong cross-border sales opportunities for partnerships, technology licensing, and distribution agreements.

Tech-Driven Capabilities With AI-driven R&D, mRNA capabilities, digital-to-biologics initiatives, and end-to-end RNA vaccine platforms in collaboration with international partners, EVA Pharma presents opportunities to co-develop or co-manufacture advanced biologics and vaccines.

Strategic Partnerships Recent and ongoing collaborations with BeiGene, Porton Advanced, DNA Script, Quantoom Biosciences, PharmaJet, Alameda Healthcare and others indicate a strong openness to joint ventures, technology transfer and regional manufacturing scale-ups that can be leveraged for sales and market access.

Affordability & Access A mission centered on sustainable access to medicines across twelve therapeutic areas, combined with large manufacturing capacity (over one million products daily) and multiple regulatory approvals, creates conversations for scalable supply contracts, private-label opportunities, and under-served market entry in emerging regions.

Immuno-Oncology & Biomaterials Upcoming immunotherapy hematology and oncology production with near-term capacity targets and viral vector/cell therapy capabilities position EVA Pharma as a strategic partner for clinical supply, contract manufacturing, and distribution of innovative oncology products.